drugset / Trial / NCT04639271
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of pyrotinib combined with trastuzumab and abraxane in HER2-positive MBC with brain metastasis.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-01-01
- Completion
- 2022-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abraxane | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Pyrotinib | Small molecule | 400 mg | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |